Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Stresses Overall Survival In Keytruda/Chemo '189 Trial Revamp

Executive Summary

Merck is changing the statistical analysis of combination study in first-line lung cancer to include dual endpoints of progression-free-survival and overall survival, and has withdrawn a filing for the combination in Europe based on mid-stage data.

Advertisement

Related Content

Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
EU CHMP OKs New Treatments For MS, Esophagitis, CMV, Hemophilia – & First Biosimilar Avastin
Questions Surround Merck’s Withdrawal Of Keytruda Filing For Lung Cancer In EU
Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel